EUVIMEDEUVIMED entdecken
KohortenstudieOpen Access

Risk of suicidal ideation and suicidality among adults prescribed semaglutide for weight management: A population‐based cohort study

Qoua L Her iD, Tiansheng Wang iD, Til Stürmer iD, John B Buse iD, Michele Jonsson Funk iD, Virginia Pate, Michael Webster-Clark iD

Diabetes, Obesity and Metabolism · 2025

DOI: 10.1111/dom.70002 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift Diabetes, Obesity and Metabolism, 2025. Verfasst von Qoua L Her und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Epidemiology, Gillings School of Global Public Health, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA. Hauptthemen laut MEDLINE: Glucagon-Like Peptides, Suicidal Ideation, Obesity, Overweight. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Division of Cancer Prevention, National Cancer Institute, National Institute on Aging of the National Institutes of Health, NCATS NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

To evaluate the risk of incident suicidal ideation (SI) and suicidality (SI , suicide attempt or intentional self‐harm) among overweight or obese adults who were prescribed semaglutide for weight management compared with active comparators (weight management drugs: bupropion/naltrexone, orlistat, phentermine or phentermine/topiramate ). Materials and Methods Using the Merative® MarketScan Databases, we conducted a retrospective cohort study of adults initiating semaglutide or an active comparator between 01 June 2021, and 31 December 2022. Patients were required to have ≥1 year of continuous health and pharmacy plan coverage, a diagnosis of overweight or obesity, no prior suicidality or type 2 diabetes, and new users of semaglutide or active comparators for inclusion. SI and suicidality were identified using diagnosis codes within 183 days of drug initiation. Kaplan–Meier analysis was used to estimate risks, risk differences (RDs), and risk ratios (RRs), controlling for confounding with standardized mortality ratio weights.

Results

Among 16 822 semaglutide and 11 986 active comparator new users, the adjusted risk of incident SI was 0.08% (13.0 events) for semaglutide and 0.05% (8.9 events) for active comparators, and for incident suicidality was 0.08% (14.0 events) for semaglutide and 0.07% (11.0 events) for active comparators. Adjusted RDs were 0.02% (95% CI: [−0.02%, 0.07%]) for SI and 0.02% (−0.03%, 0.07%) for suicidality, with corresponding RRs of 1.36 (0.62, 6.14) and 1.18 (0.57, 3.63).

Conclusion

Among patients initiating semaglutide for weight management, semaglutide did not appear to increase the risk of suicide‐related outcomes. However, the CIs of the RDs are compatible with a 0.07% increase in 6‐month risk and the true RD could be larger due to the potentially low sensitivity of ICD‐10 diagnosis codes for and underreporting of suicide‐related outcomes. Additional studies are critical to confirm these findings and obtain more precise estimates of any potential benefits or harms of semaglutide.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Glucagon-Like PeptidesSuicidal IdeationObesityOverweightAnti-Obesity AgentsHumansFemaleMaleMiddle AgedRetrospective StudiesAdultRisk FactorsSuicideAgedGlucagon-Like Peptide 1Semaglutide

Stichwörter der Autor:innen

GLP‐1RAsglucagon‐like peptide‐1 receptor agonistsobesityoverweightpatient safetysemaglutidesuicidal ideationsuicidality

Substanzen

Glucagon-Like PeptidesAnti-Obesity AgentsGlucagon-Like Peptide 1Semaglutide

Autor:innen und Institutionen

  • Department of Epidemiology, Gillings School of Global Public Health, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
  • Department of Medicine, Division of Endocrinology and Metabolism, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
  • Department of Public Health Sciences - Epidemiology and Prevention, Wake Forest University School of Medicine, Winston-Salem, North Carolina, USA.

ORCID-Profile: Qoua L Her, Tiansheng Wang, Til Stürmer, John B Buse, Michele Jonsson Funk, Michael Webster-Clark

Förderung

  • Division of Cancer Prevention, National Cancer Institute
  • National Institute on Aging of the National Institutes of Health
  • NCATS NIH HHS
  • NCI NIH HHS
  • NIDDK NIH HHS
  • American Diabetes Assocation
  • NIA NIH HHS
  • National Institute of Diabetes and Digestive and Kidney Diseases

Zitieren

APA

Her, Q. L., Wang, T., Stürmer, T., Buse, J. B., Jonsson Funk, M., Pate, V., & Webster-Clark, M. (2025). Risk of suicidal ideation and suicidality among adults prescribed semaglutide for weight management: A population‐based cohort study. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.70002

Vancouver

Her QL, Wang T, Stürmer T, Buse JB, Jonsson Funk M, Pate V, et al. Risk of suicidal ideation and suicidality among adults prescribed semaglutide for weight management: A population‐based cohort study. Diabetes, Obesity and Metabolism. 2025. doi:10.1111/dom.70002

BibTeX
@article{Her2025,
  author = {Her, Qoua L and Wang, Tiansheng and Stürmer, Til and Buse, John B and Jonsson Funk, Michele and Pate, Virginia and Webster-Clark, Michael},
  title = {Risk of suicidal ideation and suicidality among adults prescribed semaglutide for weight management: A population‐based cohort study},
  journal = {Diabetes, Obesity and Metabolism},
  year = {2025},
  doi = {10.1111/dom.70002}
}
Kostenlos starten →